Navigation Links
Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
Date:4/17/2013

SAN DIEGO, April 17, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.  

Brian M. Culley , Chief Executive Officer, said: "Increasing evidence suggests that transfusion of 'older' red blood cells (RBC) impairs clinical outcomes as a result of defects resulting from storage or age.  An NIH meta-analysis of 21 studies involving more than 400,000 patients reported that transfusion of older versus newer blood was associated with significantly increased risk of death.  Since older RBC aggregate more than younger RBC, we hypothesize that increased RBC aggregation following transfusion of older RBC or those with 'storage lesion' impairs blood flow in the microcirculation, where the majority of oxygen and nutrient exchange occur, thereby decreasing tissue perfusion and worsening outcomes." 

Mr. Culley continued: "The data presented today show that MST-188 reduced aggregation of both older and younger RBC, with a greater effect on older RBC.  If adverse clinical outcomes following transfusion are the result of increased RBC aggregation in the microcirculation, MST-188 may offer an option to improve the efficacy of transfusion.  We are conducting additional preclinical studies in this area, with the goal of helping to improve treatment options for the 4.5 million people who, in the U.S. alone, receive a transfusion each year." 

Poster Information:

  • The poster entitled "Is There a Role for a Rheologic Agent in Transfusion?" was presented by R. Martin Emanuele , Ph.D., Senior Vice President, Development
  • The poster entitled "Ev
    '/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
2. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
8. Halozyme Therapeutics Names Matt Posard to Board of Directors
9. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
10. Cell Therapeutics Secures $15 Million Loan Financing Agreement
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
... SiteJabber.com , a leading consumer protection service which helps people avoid fraudulent websites and find good sites, and LegitScript.com ... websites and avoid fraudulent ones. , ... ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 2SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 3
(Date:10/30/2014)... treatments for injuries and damage to the joints, including ... is a hard material that caps the ends of ... biomedical engineers, exploring ways to toughen up engineered cartilage ... new developments this week in the journal Proceedings ... problem with engineered tissue is that the mechanical properties ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of ... more, is currently hosting a sweepstakes on its official ... open to U.S. residents age 18 and over, and ... lucky winner will then be selected at random from ... to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez ...
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... aerobic exercise alone is best for lowering blood pressure. Researchers ... difference when it comes time to face the blood pressure ... of vigorous exertion, but exercise as a regular activity is ... the type of exercise// people engaged has made any difference ...
... arms in an accident is getting some high-tech help with ... ,Two years ago, a healthy Jesse Sullivan, 56, was ... a live wire,// costing him both his arms up to ... a traditional artificial prosthesis, relying on chains and buttons to ...
... researchers say eating milk chocolate, which is most commonly ... in the bloodstream. They found the same discouraging result ... ,The results suggest that milk and other dairy ... protective compounds in chocolate. Only subjects who ate dark ...
... SARS virus outbreak contained around the world after removing ... areas. ,SARS is thought to have originated in southern ... November. From China, experts believe the flu-like illness //was ... as far as South Africa and Canada infecting at ...
... of the most widely used disinfectants,for indoor swimming ... due to it's ability to kill Bacteria,efficiently and ... might be the likely reason for the sudden,increase ... culprit is a chemical known as trichloroamine//,(chemical name ...
... off just with the news and then following it ... disrupts their world completely. However, researchers now claim that ... of treating these cancers. Radiation oncologist Frank Vicini, M.D., ... new type of treatment called quadrant irradiation, doctors will ...
Cached Medicine News:Health News:Aerobics- right choice for Cutting Blood Pressure 2Health News:A man who lost both of his arms in an accident 2Health News:When it comes to health, all chocolates not the same. 2Health News:SARS outbreaks contained 2
... System offers strength and radiolucent capabilities ... anteater titanium microdiscectomy system for microscope-aided ... for less invasive procedures with reduced ... to provide low profile, unobstructed retraction ...
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
Medicine Products: